Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics

Standaert, David G
Boyd, James T
Odin, Per
Robieson, Weining Z
Zamudio, Jorge
Chatamra, Krai

Open link

Publication date

January 2018

DOI

10.1038/s41531-017-0040-2

Publisher

Springer Science and Business Media LLC

Abstract

Levodopa-carbidopa intestinal gel (LCIG, carbidopa-levodopa enteral suspension in the United States) is a treatment option for advanced Parkinson's disease (PD) patients with motor fluctuations. The objective of this investigation was to identify the baseline characteristics predictive of treatment response, measured by improvement in motor symptom severity, in advanced PD patients treated with LCIG during a 54-week, open-label phase 3 study. Patients with ≥1 h improvement from baseline in "Off" time were categorized as "Responders"; whereas those with <1 h improvement, any worsening, or no post-baseline assessment were "Non-Responders". A subgroup of Responders with ≥3 h improvement in "Off" time was also examined; this subgroup was identi...